Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

Background Granulosa cell ovarian tumor (GCT) is characterized by a pathognomonic mutation in the FOXL2 gene (402 C > G) that leads to an overactivation of steroidogenesis. CYP17 is a key enzyme in such process and can be inhibited by ketoconazole. Methods We designed a phase II clinical trial to...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical & translational oncology 2023-07, Vol.25 (7), p.2090-2098
Hauptverfasser:	Garcia-Donas, Jesus, Hurtado, Alicia, Garrigos, Laia, Santaballa, Ana, Redondo, Andres, Vidal, Laura, Lainez, Nuria, Guerra, Eva, Rodriguez, Victor, Cueva, Juan, Bover, Isabel, Palacio, Isabel, Rubio, Maria Jesus, Prieto, Mario, Lopez-Guerrero, Jose Antonio, Rodriguez-Moreno, Juan Francisco, Garcia-Casado, Zaida, Garcia-Martinez, Elena, Taus, Alvaro, de Castro, Ignacio Pérez, Navarro, Paloma, Grande, Enrique
Format:	Artikel
Sprache:	eng
Schlagworte:	Medicine Medicine & Public Health NCT NCT01584297 Oncology Research Article
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!